Norway (NO)

Accuracy and
reliability

The FreeStyle Libre 3 system delivers outstanding

performance and improves clinical outcomes 

FreeStyle Libre 2 system
FreeStyle Libre 2 system
FreeStyle Libre 2 system

Consensus Error Grid for the FreeStyle Libre 3 system compared
with reference4

MARD=mean absolute relative difference; YSI=Yellow Springs
Instruments; glucose sensing technology reliability defined by
signal connection.

The only CGM with
sub-8% overall MARD1-3

The FreeStyle Libre 3 system is accurate3, stable and
consistent over 14 days – no finger pricks5, no user
calibration, no code entry.

  • 7.8% overall MARD1 – the lower the MARD, the more
    accurate the results.

  • 93.3% within ±20% and 93.4% within ±20%. Percentage
    of readings within ±20 mg/dL of YSI values for glucose
    levels <70 mg/dL and ±20% when ≥70 mg/dL1

  • 99.9% in zones A and B of Consensus Error Grid1

Excellent accuracy in the low through
high glucose ranges3

YSI Plasma venous blood glucose reference using the YSI 2300 STAT PLUS Glucose and Lactate Analyzer

Overall 

performance3

Accuracy

                    

FreeStyle Libre 3 system accuracy study

FreeStyle Libre 3 Accuracy Study, ATTD 2022 Commercial Symposium

5x more readings power up to 5x faster alarms6

With readings every minute, the FreeStyle Libre 3 system provides 5x faster readings and alarms6 than other
leading brands and is the most reliable CGM for signal strength.7,8

5x more readings power up to 5x faster alarms

Example: Glucose is dropping at 3mg/dL per minute. The low glucose alarms is set at 70 mg/dL.

FreeStyle Libre 3 - Empowerment Every Minute, ATTD 2022 Commercial Symposium

The FreeStyle Libre 3 system outperforms other CGMs on connectivity7

The FreeStyle Libre 3 system delivers performance your patients can count on – so they won't miss a low glucose
alarm8 or possible hypo.

Strongest Bluetooth integration7

10-meter range is more than 50% further than other CGMs7.

Longest data storage9

15-day data storage makes data gaps a thing of the past.

Improved clinical outcomesφ,10-12

With outstanding accuracy,3 best-in-class connectivity7 and readings every minute, patients can act faster to
reduce hypoglycaemia and improve overall glucose control10-14.

Figure Hab1c

FreeStyle Libre 2 significantly
reduced time spent below target
range (<70 mg/dL) by 43 minutes
per day in people with T1D10

Figure Hab1c

Reduces nocturnal hypoglycaemia
in T2D (<70 mg/dL, time in hour,
from 11:00 pm to 6:00 am)
(p<0.0001)11

Figure Hab1c

Reduces serious hypoglycaemia in
T2D (<55 mg/dL, time in hour, within
24 hours)
(p<0.0014)11

Figure Hab1c

0.55% average reduction in A1c

observed at 2-4 months, sustained 

for 12 months13,14

Figure Hab1c

People with T1D increased their time
in range by more than 2 hours per
day using FreeStyle Libre 2
compared to SMBG10

Clinical benefits of continuous glucose monitoring

CGM Accuracy & Performance, ATTD 2022 Commercial Symposium

The FreeStyle Libre 3 system delivers outstanding accuracy3, reliability and clinical benefits

Outstanding accuracy across
multiple measures, including
strong low-end performance3

Figure Hab1c

Real-time readings updated
every minute—5x faster than
any other CGMs15

Figure Hab1c

Significant improvement in
clinical outcomes10-12, φ

Learn more about the FreeStyle Libre 3 digital ecosystem

FreeStyle Libre 3 system

FreeStyle Libre 3 App

LibreLinkUp

LibreView

φStudies data are collected with the FreeStyle Libre system or FreeStyle Libre 2 system and is applicable to the FreeStyle Libre 3 system based on technological similarities.

* Data on file, Abbott Diabetes Care, Inc. Based on the number of users worldwide for the FreeStyle Libre portfolio compared to the number of users for other leading personal use sensor-based glucose monitoring systems.

References & Disclaimers

  1. FreeStyle Libre 3 User Manual. FreeStyle Libre 3 demonstrates 7.8% overall MARD with 7.5% adult MARD and 8.6% pediatric MARD (age 6-17) in accuracy to YSI reference.
  2. Comparison based on publicly available information. Data on file, Abbott Diabetes Care, Inc.
  3. Alva, S. et al. Diabetes Ther. (2023); doi: 10.1007/s13300-023-01385-6.
  4. Data on file, Abbott Diabetes Care, Inc.
  5. Finger pricks are required when glucose readings and alarms do not match symptoms or expectations.
  6. Dexcom G6 CGM User Guide and Medtronic Guardian Connect System User Guide.
  7. Data on file. Abbott Diabetes Care, Inc. Based on the signal strength in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide.
  8. Notifications will only be received when alarms are turned on and the sensor is within 10 meters unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts. See the FreeStyle Libre 3 User’s Manual for more information.
  9. Data on file. Abbott Diabetes Care, Inc. Based on the data storage in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide.
  10. Leelarathna, L. et al. N Engl J Med (2022): https://doi.org/10.1056/NEJMoa2205650.
  11. Haak, T. et al. Diabetes Ther. (2017): https://doi.org/10.1007/s13300-016-0223-6.
  12. Yaron, M. et al. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166.
  13. Evans, M. et al. Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00720-0.
  14. NOTE: statistically significant A1c reduction based on the confidence interval range.
  15.  Based on the reading frequency in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide compared to readings every minute for FreeStyle Libre 3 system sensors.
Error 500 Modal
Myfreestyle Landing Page
Myfreestyle Landing Page Secure
Login Page
Hvorfor FreeStyle Libre systemet?
FREESTYLE PORTEFØLJE
VITENSKAPELIGE RESSURSER - OG UTDANNING
Nyheter og eventer
HJELP
Abbott

© 2023 Abbott. FreeStyle, Libre, og relaterte merkevarer eies av Abbott. Andre varemerker tilhører deres respektive eiere. ADC-72789 V2.0 05/23

Please click "Accept Sale/Sharing and Targeted Advertising" to enable full site functionality.

At this time, we are experiencing problems with broken links on our site. As an interim solution, for full site functionality you must enable functional and advertising cookies. If you continue to opt-out of these cookies, some content on our site may not be viewable.

We use functional cookies to analyze your use of the site, improve performance and provide a better customer experience. We use advertising cookies to allow us, through certain data assigned and obtained from the user's device, to store or share with third parties information related to user's browsing activity in our website, in order to create an advertising profile and place relevant advertising in our website or those third parties websites. For more information about how Abbott uses cookies please see our Cookie Policy and Privacy Policy

In order to accept functional and advertising cookies, please click "Enable Cookies" and then click "Accept Sale/Sharing and Targeted Advertising" to view the full site.

Collapse
Learn more about cookies

Vil du forlate denne siden?

Lenken "Ja" nedenfor tar deg til et nettsted som ikke tilhører Abbott Laboratories. Lenker til andre nettsteder er ikke under kontroll av Abbott Laboratories, og Abbott Laboratories er ikke ansvarlig for innholdet på slike nettsteder eller noen lenker på slike nettsteder. Abbott Laboratories gir disse lenkene til deg kun som en bekvemmelighet, og inkluderingen av en lenke innebærer ikke at Abbott Laboratories godkjenner nettstedet.

Vil du forlate denne siden?

Nettstedet er beregnet på helsepersonell som jobber i Norge.

Dette er et produktspesifikt nettsted kun beregnet for helsepersonell i Norge. Hvis du bor i et annet land, kontakt ditt lokale Abbott-kontor for å få riktig produktinformasjon for ditt land.

Tar deg til pasientsiden

Tar deg til helsepersonellsiden